What a 30% rise in coupling-reagent prices does to a 15 mg vial
Follow the resin, not the catalogue.
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Page 6 of 67 of this archive, newest first.
Follow the resin, not the catalogue.
Reported from the analysis, not from a warning notice.
Reported from the analysis, not from a warning notice.
What happens to traceability when bulk material is subdivided, repackaged and relabelled two or three times before sale.
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Reported from the analysis, not from a warning notice.
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Follow the resin, not the catalogue.
Every third-party report in this market describes a sample somebody chose to send. That choice is outside the laboratory’s control and outside its records.
Reported from the analysis, not from a warning notice.
Follow the resin, not the catalogue.
Reported from the analysis, not from a warning notice.
The route did not close because of a rule about peptides.
Reported from the analysis, not from a warning notice.
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Every certificate circulating in this market answers a question about molecules. Almost none answers a question about organisms, pyrogens, or the integrity of the seal.
A result on one vial generalises to a batch only if the vial was drawn in a way that makes it representative — and nobody records how it was drawn.
Follow the resin, not the catalogue.
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Reported from the analysis, not from a warning notice.